These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30106659)

  • 1. Off-Label Marketing's Audiences: The 21
    Halabi SF
    Am J Law Med; 2018 May; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 3. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 4. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 5. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 6. Hidden truth: The perils and protection of off-label drug and medical device promotion.
    Conko G
    Health Matrix Clevel; 2011; 21(1):149-87. PubMed ID: 21847900
    [No Abstract]   [Full Text] [Related]  

  • 7. An unhealthy disregard.
    Nat Med; 2010 Jun; 16(6):609. PubMed ID: 20526289
    [No Abstract]   [Full Text] [Related]  

  • 8. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract]   [Full Text] [Related]  

  • 10. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
    Larkin I; Ang D; Avorn J; Kesselheim AS
    Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating promotional claims as false or misleading.
    Brushwood DB; Knox CA; Liu W; Jenkins KA
    Am J Health Syst Pharm; 2013 Nov; 70(21):1941-4. PubMed ID: 24128969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
    Greenwood K
    Am J Law Med; 2011; 37(2-3):278-98. PubMed ID: 21847882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L
    Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
    [No Abstract]   [Full Text] [Related]  

  • 14. GlaxoSmithKline is fined record $3bn in US.
    Roehr B
    BMJ; 2012 Jul; 345():e4568. PubMed ID: 22761252
    [No Abstract]   [Full Text] [Related]  

  • 15. When Does FDAMA Section 114 Apply? Ten Case Studies.
    Neumann PJ; Saret CJ
    Value Health; 2015 Jul; 18(5):682-9. PubMed ID: 26297097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The commercial speech doctrine in health regulation: the clash between the public interest in a robust First Amendment and the public interest in effective protection from harm.
    Orentlicher D
    Am J Law Med; 2011; 37(2-3):299-314. PubMed ID: 21847883
    [No Abstract]   [Full Text] [Related]  

  • 17. Defining "True and Non-Misleading" for Pharmaceutical Promotion.
    Hey SP; Kesselheim AS
    J Law Med Ethics; 2018 Jun; 46(2):552-554. PubMed ID: 30146990
    [No Abstract]   [Full Text] [Related]  

  • 18. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK; Liang BA
    Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416
    [No Abstract]   [Full Text] [Related]  

  • 19. Certification denied in pharmaceutical class action.
    Boudreau A; Tombs A
    Health Law Can; 2012 Aug; 33(1):1-4. PubMed ID: 23097924
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.